TAT Technologies Ltd., a supplier in commercial and military aviation and defense, will release its Q3 2026 financial results on November 2 before market open. The company will host a webcast and conference call at 8:00 a.m. Eastern Time to discuss the results. Investors can register for the webcast via the company’s website. This update provides insight into TAT's financial performance and outlook for the period ending September 30, 2026.
TAT Technologies' upcoming Q3 2026 results provide context for readers interested in industrials. For readers following the Industrials sector, here is Pluang's market snapshot as of Oct 28, 2026 03:12 WIB: out of 135 priced US Industrials stocks tradable on Pluang, 84 rose and 51 fell today. Notable movers include JBLU at USD 2.82 with a 1-day change of +18.99% and a balanced Pluang order activity of 50% Sell / 50% Buy, TE at USD 2.47 with a 1-day change of +16.51% and 79% Buy activity, and XYL at USD 93.40 with a 1-day change of -13.71% and 97% Buy activity. The most notable figure is JBLU's 18.99% price increase.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
